Epigral Ltd (EPIGRAL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Epigral Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of Conference Call discussing Q2 FY27 Results held on Monday, 2nd November, 2026 at 5.00 P.M.
Audio / Video · 03 Nov 2026, 4:33 am
Epigral Releases Audio Recording of Q2 FY27 Earnings Conference Call Epigral Limited announced that the audio recording for its earnings conference call discussing Q2 FY27 financial results is publicly available. The call was conducted on 2nd Nov'26 at 5:00 PM. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the recording has been uploaded to the company's official website and can be accessed via the designated investor relations portal.
INVESTOR PRESENTATION - Q2 FY27.
Investor Presentation · 02 Nov 2026, 7:32 pm
Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion Epigral reported Q2 FY27 revenue growth of 28% YoY to ₹752 Cr, supported by a 6% YoY sales volume increase and improved realizations. Derivatives & Specialty chemicals contributed 57% of total revenue. EBITDA rose 3% YoY to ₹136 Cr, with margins contracting to 18% due to elevated raw material costs, while PAT grew 26% YoY to ₹64 Cr. For H1 FY27, revenue reached ₹1,461 Cr and PAT stood at ₹164 Cr. Expansions in CPVC and ECH are scheduled for commissioning in Q3 FY27.
PRESS RELEASE - RESULTS- Q2 FY27.
Press Release · 02 Nov 2026, 7:29 pm
Epigral Reports Strong Q2 FY27 With PAT Surging 26% YoY to ₹64 Crore Epigral reported a 26% YoY rise in Q2 FY27 PAT to ₹64 Cr, while revenue increased 28% YoY to ₹752 Cr, driven by improved realisations and 6% sales volume growth. Derivatives and Specialty contribution rose to 57% of revenue versus 50% in Q2 FY26. EBITDA grew to ₹136 Cr, with margins at 18% due to elevated raw material costs. For H1 FY27, revenue reached ₹1,461 Cr and PAT hit ₹164 Cr. Expansions in CPVC and ECH are slated for commissioning within a quarter.
UNAUDITED FINANCIAL RESULTS - 30.09.2026
Financial Result · 02 Nov 2026, 7:26 pm
Epigral Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 02 Nov 2026, 7:22 pm
Outcome of Board Meeting held on Monday, 2nd November, 2026 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the Second Quarter and Half Year ended 30th, September, 2026
Outcome · 02 Nov 2026, 7:20 pm
Epigral Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 746 (+27.0% YoY | +5.8% QoQ) ■ EBITDA: 136 (+2.8% YoY | -24.0% QoQ) ■ EBITDA Margin (%): 18.2 (-429 bps YoY | -716 bps QoQ) ■ PAT: 65.1 (+27.1% YoY | -34.8% QoQ) ■ EPS (INR): 15.1 (+27.1% YoY | -34.7% QoQ)
The Company hereby submits the revised credit rating.
Others (Uncategorized) · 30 Oct 2026, 4:33 am
CRISIL Assigns Revised Ratings to Epigral Limited's Bank Facilities CRISIL Ratings has assigned revised credit ratings for Epigral Limited's total bank loan facilities amounting to Rs. 1,050 Crore as of 28th Oct'26. The agency assigned a long-term rating of CRISIL AA/Stable and a short-term rating of CRISIL A1+ to the company's facilities.
Intimation of assessment order for A.Y. 2023-24 pertaining to F.Y. 2022-23, along with notice of demand of Rs.28.11 crore (including applicable interest).
Others (Uncategorized) · 30 Oct 2026, 12:25 am
Epigral Limited Receives ₹28.11 Crore Income Tax Demand for AY 2023-24 Epigral Limited received an assessment order and demand notice of ₹28.11 crore (including interest) for AY 2023-24 (FY 2022-23) from the Deputy Commissioner of Income Tax, Vadodara, on 28th Oct'26. The order was issued under section 143(3) read with section 144C(13) and section 156 of the Income-tax Act, 1961. The company stated the demand is not maintainable, sees no financial or operational impact, and is filing a rectification application and appeal within prescribed timelines.
Epigral Limited informs that Conference Call is scheduled on Monday, 2nd November, 2026 to discuss Q2 FY27 Results.
Intimation · 02 Nov 2026, 5:00 pm
Epigral Schedules Q2 FY27 Earnings Conference Call Epigral Limited will host an earnings conference call on 2nd Nov'26 at 5:00 PM IST to discuss its Q2 FY27 financial results. Organised by Emkay Global Financial Services Ltd, the call will feature senior management, including Chairman and Managing Director Maulik Patel, Executive Director Kaushal Soparkar, Chief Financial Officer Rakesh Agrawal, and Investor Relations lead Milind Kotecha. Investors can join via universal dial-in numbers (+91 22 6280 1325 / +91 22 7115 8226) or global toll-free access.
Epigral Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
Epigral Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Un-audited Financial Results (Standalone ....
Intimation · 02 Nov 2026, 5:30 am
Epigral Board to Consider Q2 and H1 Financial Results on 2nd Nov'26 Epigral Limited has scheduled its Board of Directors meeting for 2nd Nov'26 to consider, approve, and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. The board will also review the Statutory Auditors' Limited Review Report for the period, in compliance with Regulation 29 of SEBI LODR Regulations, 2015.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Epigral Limited has informed the Exchange about Investor / Analyst Plant Visit on Thursday, 22.10.2026
Intimation · 21 Oct 2026, 3:33 pm
Epigral Limited Schedules Dahej Plant Visit for Elara Securities Epigral Limited informed stock exchanges under Regulation 30 of SEBI LODR Regulations regarding an upcoming physical plant visit by Elara Securities (India) Pvt. Ltd. at its Dahej, Gujarat facility. The visit is scheduled for Thu, 22nd Oct'26, subject to potential changes due to exigencies. The company confirmed that no unpublished price-sensitive information (UPSI) will be shared or discussed during the interaction.
Epigral Limited informs that the Company is having One-on-One Meeting with Investor / Analyst on Wednesday, 13th October, 2026.
Intimation · 13 Oct 2026, 10:57 pm
Epigral Schedules One-on-One Investor Meeting with Elara Securities Epigral Limited announced a one-on-one investor meeting with Elara Securities (India) Pvt Ltd scheduled for 14th Oct'26 via video conferencing. Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the company confirmed that no unpublished price sensitive information will be shared or discussed during the interaction. The schedule remains subject to change due to operational exigencies.
Epigral Limited ('the Company') hereby informs that the officials of the Company are participating in Anand Rathi Annual Flagship Conference: G-200 Summit 2026 scheduled on 21.09.2026.
Intimation · 16 Sept 2026, 11:28 pm
Epigral to Participate in Anand Rathi G-200 Summit 2026 Epigral Limited announced that company officials will participate in the Anand Rathi Annual Flagship Conference: G-200 Summit 2026. The investor conference is scheduled to take place on 21st Sep'26 in Mumbai. The company confirmed that no unpublished price-sensitive information will be shared or discussed during the interactions.
Epigral Limited has informed the Exchange about Investor / Analyst Plant Visit on Thursday, 03.09.2026
Intimation · 31 Aug 2026, 11:19 pm
Epigral Schedules Analyst Plant Visit with Bellwether Capital Epigral Limited will host Bellwether Capital for a plant visit on 3rd Sep'26 at its Dahej, Gujarat facility. The company has stated that no unpublished price-sensitive information will be shared during the visit. This intimation was filed with the stock exchanges on 31st Aug'26. The schedule is subject to change based on any exigencies.
Epigral Limited has informed the Exchange about One-on-One Meeting with Investor / Analyst on thursday, 20.08.2026
Intimation · 19 Aug 2026, 12:10 am
Epigral Schedules One-on-One Meeting with Incred Research Services Epigral Limited will hold a one-on-one meeting with Incred Research Services Pvt. Ltd. on 20 Aug'26 in Ahmedabad. The company confirmed that no unpublished price-sensitive information will be discussed during the meeting. The discussion will be based on the latest earnings and corporate presentations already available on the company's website. The schedule is subject to change.
Epigral Limited hereby informs that the officials of the Company are participating in EMKAY Confluence 2026 on 12th August, 2026
Intimation · 07 Aug 2026, 10:18 pm
Epigral Limited to Participate in EMKAY Confluence 2026 Epigral Limited has informed exchanges that its officials will participate in the EMKAY Confluence 2026. The investor conference is scheduled to be held in Mumbai on 12th Aug'26. This intimation was made pursuant to SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
Epigral Limited informs that the Company is having One-on-One Meeting with Investor / Analyst on Monday, 3rd august, 2026.
Intimation · 31 Jul 2026, 1:12 am
Epigral Schedules One-on-One Investor Meeting with VVD Asset Managers Epigral Limited announced a one-on-one meeting with investor/analyst VVD Asset Managers. The meeting is scheduled for 3rd Aug'26 in Ahmedabad. The company confirmed that no unpublished price-sensitive information will be discussed. Discussion points will be limited to information already available in the latest Earnings and Corporate Presentations accessible on the company's website. The schedule remains subject to change.
Epigral Limited submits Transcript of Conference Call discussing Q1 FY27 Results.
Transcript · 31 Jul 2026, 1:09 am
Audio Recording of Conference Call discussing Q1 FY27 Results held on Monday, 27th July, 2026 at 5.00 p.m.
Audio / Video · 28 Jul 2026, 3:52 am
Epigral Q1 FY27 Results Conference Call Audio Recording Released Epigral Limited has released the audio recording of its conference call held on 27th Jul'26 at 5:00 p.m. The call discussed the company's financial and operational performance for the first quarter of fiscal year 2027. This regulatory filing complies with SEBI (LODR) Regulations, 2015. The recording is accessible on the company's website, providing investors and analysts with direct insights from management regarding the quarterly results.
Investor Presentation Q1 FY 27.
Investor Presentation · 27 Jul 2026, 7:44 pm
Epigral Q1FY27: Revenue Up 15% YoY, Announces Major Capex in Epoxy Resin Epigral reported Q1FY27 revenue of ₹709 Crore, up 15% YoY, driven by 5% volume growth. EBITDA grew 10% YoY to ₹179 Crore with a 25% margin, while PAT rose 25% to ₹99 Crore. Net Debt/EBITDA stood at 0.8x as of 30th Jun'26. The board approved new capex for an Epoxy Resin plant (1,25,000 TPA) and a Multi-Purpose Plant, both expected to commission by H2FY28. Ongoing expansions for CPVC and ECH are on schedule for Q2FY27 commissioning.
Press Release of Un-Audited Financual results - Q1FY27.
Press Release · 27 Jul 2026, 7:42 pm
Epigral Q1FY27 PAT Jumps 25% YoY; Announces ₹600 Crore Capex Epigral reported strong Q1FY27 results, with PAT growing 25% YoY to ₹99 Cr and revenue increasing 15% to ₹709 Cr. EBITDA rose 10% YoY to ₹179 Cr, though EBITDA margin contracted slightly to 25%. The board approved a significant ₹600 Cr capex for a new Epoxy Resin plant (1,25,000 TPA) and a Multi-Purpose Plant. This forward integration leverages existing raw material production (ECH, Caustic Soda) and targets high-growth specialty chemical markets. The new plants are expected to be commissioned by H2FY28.
As part of the Company''s strategic growth and expansion initiatives, it proposes to establish a new manufacturing facility for Epoxy Resin and formulations and Multi Purpose Plant at its ....
Outcome · 27 Jul 2026, 7:39 pm
Epigral Announces ₹600 Cr Capex for New Epoxy Resin and MPP Facility Epigral Limited announced a strategic expansion at its Dahej facility, establishing a new manufacturing plant for Epoxy Resin & Formulations and a Multi-Purpose Plant (MPP). The project involves an estimated capital expenditure of ₹600 Cr, financed through a mix of debt and internal accruals. The Epoxy Resin facility will have a proposed capacity of 1,25,000 TPA. Both plants are expected to be commissioned by H2 FY28, aiming to expand the product portfolio and meet growing demand.
Outcome of Board Meeting held on Monday, 27th July, 2026 and submission of Un-Audited Financial Results (Standalone & Consolidated) for the First Quarter ended 30th June, 2026.
Outcome · 27 Jul 2026, 7:26 pm
Epigral Q1 FY27 Standalone PAT Declines 38% YoY Despite Revenue Growth Epigral reported a standalone PAT of ₹99.18 crore for Q1 FY27, a 38.2% YoY decline from ₹160.41 crore, impacted by higher material costs and a negative tax reversal in the base quarter. Revenue from operations grew 16.3% YoY to ₹705.36 crore. On a QoQ basis, PAT increased by 21.1% from ₹81.93 crore while revenue saw a marginal decline of 4.2%. Total expenses rose 13.4% YoY to ₹576.28 crore. The company also announced the incorporation of a wholly-owned subsidiary, Epigral Advanced Material Limited.